Desk›Healthcare› Genomic Valley Biotech Ltd
Genomic Valley Biotech Ltd
BSE 539206 · NSE GVBL · ISIN INE574D01010 · Group X · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
₹28.87
+0.00%
BSE close, 28 August 2026
₹8.82 cr
0.3 cr shares · Micro cap
₹4.76 cr
as published
412.4× · 2.31×
EPS ₹0.07 · BV ₹12.50
0.27 / 0.03
₹ cr, as filed
6
2 selected · 33%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -37.9% |
|---|---|
| Against 52-week low | +43.6% |
| Day change | +0.00% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.07 |
|---|---|
| Price / earnings | 412.43× |
| Price / book | 2.31× |
| Book value — derived, price ÷ P/B | ₹12.50 |
| Return on equity | 0.55% |
| Operating margin | 42.11% |
| Net margin | 39.47% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 0.56%
- ROE as published
- 0.55%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 0.04 | 0.02 | 0.05 | 42.11% | 39.47% |
| Mar-26 · Q | 0.04 | -0.01 | -0.03 | 7.89% | -21.05% |
| FY25-26 | 0.27 | 0.03 | 0.10 | 16.42% | 11.19% |
Quarter on quarter
- Revenue, quarter on quarter
- +0.0%
- Net profit, quarter on quarter
- +300.0%
- Operating margin, quarter on quarter
- +3,422 bps
Disclosure profile 6 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Results | 1 |
| Selected sub-total | 2 |
| Procedural | |
| Board Meeting | 1 |
| Newspaper Publication | 1 |
| Other Update | 1 |
| Trading Window | 1 |
| Procedural sub-total | 4 |
| Total | 6 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
6 filings · 2 selected · busiest 2026-08-14
Filing rhythm · the twelve most recent
2026-08-062026-09-28
SelectedProcedural
Filings
6 in the window · 2 earlier on record
-
28 September 2026 ·
Closure of Trading Window
Please find enclosed herewith intimation for closure of trading window.
Insider Trading / SAST / Closure of Trading Window View filing →
-
31 August 2026 ·
Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2026, Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation of approval of Extension of time for holding Annual General Meeting (AGM) of the company for the financial year ended on 31st March 2026, pursuant to regulation 30 of SEBI (Listing ....
Others View filing →
-
17 August 2026 ·
Newspaper Publication
Please find enclosed herewith unaudited financial results for the quarter ended on 30th June, 2026.
Company Update / Newspaper Publication View filing →
-
14 August 2026 ·
Results-Financial Results For Quarter Ended On 30 June 2026.
Unaudited financial results for Quarter ended on 30 June 2026.
Result / Financial Results View filing →
-
14 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Held On Today I.E. 14Th August 2026
Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026.
Board Meeting / Outcome of Board Meeting View filing →
-
6 August 2026 ·
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone) Of The Company For The Quarter Ended On June 30, 2026
Genomic Valley Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve unaudited financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Genomic Valley Biotech Ltd · the 50 most recent filings